(19)
(11) EP 2 523 666 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
06.04.2016 Bulletin 2016/14

(45) Mention of the grant of the patent:
13.01.2016 Bulletin 2016/02

(21) Application number: 11733156.1

(22) Date of filing: 14.01.2011
(51) International Patent Classification (IPC): 
A61K 31/57(2006.01)
A61K 47/44(2006.01)
C07J 5/00(2006.01)
 A61K 31/575(2006.01)
A61P 25/00(2006.01)
C07J 9/00(2006.01)
(86) International application number:
PCT/SE2011/050036
(87) International publication number:
WO 2011/087441 (21.07.2011 Gazette 2011/29)

(54)

A PHARMACEUTICAL COMPOSITION COMPRISING 3-BETA-HYDROXY-5-ALPHA-PREGNAN-20-ONE WITH IMPROVED STORAGE AND SOLUBILITY PROPERTIES

PHARMAZEUTISCHE ZUSAMMENSETZUNG MIT 3-BETA-HYDROXY-5-ALPHA-PREGNAN-20-ON MIT VERBESSERTEN LAGERUNGS- UND LÖSLICHKEITSEIGENSCHAFTEN

COMPOSITION PHARMACEUTIQUE COMPRENANT 3-BETA-HYDROXY-5-ALPHA-PREGNAN-20-ONE A PROPRIETES DE STOCKAGE ET DE SOLUBILITE AMELIOREES

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 14.01.2010 US 295027 P
14.01.2010 SE 1050029

(43) Date of publication of application:
21.11.2012 Bulletin 2012/47

(73) Proprietor: Asarina Pharma AB
171 65 Solna (SE)

(72) Inventors:
  • BÄCKSTRÖM, Torbjörn
    S-907 38 Umeå (SE)
  • CARLSSON, Anders
    S-112 36 Stockholm (SE)

(74) Representative: Awapatent AB 
P.O. Box 45086
104 30 Stockholm
104 30 Stockholm (SE)


(56) References cited: : 
WO-A1-99/45931
 WO-A2-2006/037016
   
  • GONZALEZ-MARISCAL, G. ET AL.: 'Anesthetic pregnanes counteract androgen-induced defeminization.' NEUROENDOCRINOLOGY vol. 34, no. 5, 1982, pages 357 - 362
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).